$-1.60 EPS Expected for Agios Pharmaceuticals, Inc. (AGIO)

April 21, 2018 - By Kenneth Lin

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. It increased, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported.
Oppenheimer reported 20,099 shares or 0.03% of all its holdings. 3,690 were reported by Trexquant Invest Limited Partnership. Lazard Asset Ltd Llc has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Proshare Advsr Ltd invested in 0.01% or 27,384 shares. California State Teachers Retirement Sys reported 66,141 shares or 0.01% of all its holdings. Pnc Service holds 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 99 shares. Moreover, Weiss Asset Mgmt Limited Partnership has 0.04% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 7,462 shares. Metropolitan Life Insur Ny reported 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Bnp Paribas Asset Mngmt invested in 252,160 shares or 0.12% of the stock. Arrowmark Colorado Llc reported 0.08% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). 2.81M are held by Blackrock. Bnp Paribas Arbitrage has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Artal Grp Sa has invested 0.43% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Contravisory Invest Mgmt owns 5 shares. 20,019 are held by Sivik Glob Healthcare Limited Liability Com.

Since January 10, 2018, it had 1 buy, and 20 sales for $17.04 million activity. Schenkein David P also sold $1.01M worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. 2,050 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares with value of $161,192 were sold by Hoerter Steven L.. $170,190 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Bowden Christopher. On Friday, January 12 Alenson Carman sold $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,150 shares. Another trade for 3,000 shares valued at $225,607 was sold by Biller Scott. Scadden David bought $16,688 worth of stock.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.60 EPS on May, 4 before the open.They anticipate $0.04 EPS change or 2.56 % from last quarter’s $-1.56 EPS. After having $-1.81 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -11.60 % EPS growth. The stock decreased 2.08% or $1.84 during the last trading session, reaching $86.45. About 324,378 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 21, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 4 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agios Pharmaceuticals had 7 analyst reports since November 2, 2017 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Sunday, November 19 by SunTrust. As per Thursday, November 2, the company rating was maintained by Credit Suisse. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by RBC Capital Markets on Wednesday, February 14. The rating was maintained by RBC Capital Markets on Wednesday, November 1 with “Buy”. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Overweight” rating by JP Morgan on Thursday, February 15. The rating was maintained by Credit Suisse on Thursday, February 15 with “Buy”. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, April 11.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.96 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: